Your new post is loading...
Reverse Translational Medicine™ (RTM™) is Neurimmune’s proprietary technology platform. It is based on the scientific understanding and high-throughput analyses of human immune responses to disease-related proteins in selected populations including elderly with the capability to stay healthy during the aging process.
Neurimmune’s recombinant human monoclonal antibody therapeutics combine the full complement of advantages provided by human affinity maturation and tolerance selection. These processes are biologically optimized through evolutionary processes over millions of years providing unsurpassed efficacy and safety in human subjects.
Neurimmune’s molecular engineering technology preserves favorable immunobiological features of human-derived antibodies creating an entirely novel generation of highly optimized biopharmaceutical drugs.
With their superior biophysical, pharmacological and safety properties,
Neurimmune’s therapeutic antibodies combine first-in-class with best-in-class potential. As a result, they provide considerable advantages over competing products generated by conventional target-to-lead development cycles commonly applied by the biopharmaceutical industry.
Via Krishan Maggon
Neurimmune aims at the development of disease-modifying treatments for Alzheimer’s disease, and partnered its first RTMTM-derived antibody program Aducanumab (BIIB037) with Biogen Idec in 2007. Aducanumab (BIIB037) is a recombinant human monoclonal antibody targeting Abeta aggregates that are thought to play a role in the neurodegenerative process in Alzheimer’s disease. Aducanumab (BIIB037) is currently being investigated in a Phase 1b study (PRIME) in patients with prodromal and mild Alzheimer’s disease. The interim analysis showed a dose-dependent, time-dependent, and statistically significant reduction of beta-amyloid from the brain along with an effect on cognition in patients with prodromal or mild Alzheimer's disease.
In 2010, Neurimmune also partnered its second AD program NI-105 on recombinant human monoclonal antibodies targeting tau with Biogen Idec.
Neurimmune aims at the development of disease-modifying treatments for Alzheimer’s disease, and partnered its first RTMTM-derived antibody program Aducanumab (BIIB037) with Biogen Idec in 2007. Aducanumab (BIIB037) is a recombinant human monoclonal antibody targeting Abeta aggregates that are thought to play a role in the neurodegenerative process in Alzheimer’s disease. Aducanumab (BIIB037) is currently being investigated in a Phase 1b study (PRIME) in patients with prodromal and mild Alzheimer’s disease. The interim analysis showed a dose-dependent, time-dependent, and statistically significant reduction of beta-amyloid from the brain along with an effect on cognition in patients with prodromal or mild Alzheimer's disease.
In 2010, Neurimmune also partnered its second AD program NI-105 on recombinant human monoclonal antibodies targeting tau with Biogen Idec.